The Food and Drug Administration today said it no longer authorizes the use of hydroxychloroquine or chloroquine as an effective treatment of COVID-19.

FDA cited serious side effects, such as cardiac adverse events, in its decision, stating that it considered results from a large trial and found neither drug to “be effective in treating COVID-19, nor is it reasonable to believe that the known and potential benefits of these products outweigh their known and potential risks.” FDA said patients who have already been administered the drugs that were distributed under the original emergency use authorization may continue their use if deemed necessary by physicians.

Related News Articles

#HealthCareInnovation Thursday Blog
Early on in my professional journey as a physician, I had a calling to work with infectious diseases. Little did I know then how big a role this medical…
Headline
On Dec. 15, the Department of Health and Human Services will stop collecting hospitals’ COVID-19 data through the TeleTracking portal and begin collecting the…
Headline
Centers for Disease Control and Prevention Director Rochelle Walensky, M.D., today encouraged all eligible Americans to get vaccinated against the flu and…
Headline
The Food and Drug Administration does not currently authorize the monoclonal antibody bamlanivimab for emergency use to treat mild-to-moderate COVID-19 in the…
Headline
In a study of symptomatic adults tested for SARS-CoV-2 at U.S. pharmacies since Sept. 14, bivalent COVID-19 vaccine boosters provided additional protection…
Headline
The Biden Administration today launched a six-week campaign to encourage Americans to get an updated COVID-19 vaccine. In addition to ongoing pop-up clinics,…